Skip to main content

Table 7 Characteristics of the patient population

From: Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites

  Total Cancer patients Non-cancer patients
Age 283 (100 %) 134 (100 %) 149 (100 %)
≤50 years 57 (20 %) 20 (15 %) 37 (25 %)
51–60 years 67 (24 %) 26 (19 %) 41 (28 %)
>60 years 159 (56 %) 88 (66 %) 71 (48 %)
Median age (years) 62 67 60
Age range (years) 23–87 39–87 23–87
Follow-up    
Death 99 (35 %) 61 (46 %) 38 (26 %)
Alive 184 (65 %) 73 (54 %) 111 (74 %)
Mean follow-up (days) 162 141 180
Median follow-up (days) 59 56 83
Range (days) 0–832 0–832 0–774
Gender    
Female 121 (43 %) 62 (46 %) 59 (40 %)
Male 162 (57 %) 72 (54 %) 90 (60 %)
Non-malignant disease    
Hepatic failure 180 (63 %) 49 (36 %) 131 (88 %)
Gastrointestinal disease 104 (37 %) 36 (27 %) 68 (46 %)
Cardiac disease 80 (28 %) 33 (24 %) 47 (32 %)
Renal failure 47 (17 %) 22 (16.%) 25 (17 %)
Hepatitis A, B, C, D, or E, or autoimmune disease 46 (16 %) 18 (13 %) 28 (19 %)
Hepatorenal syndrome 40 (14 %) 11 (8 %) 29 (19 %)
Portal hypertension 25 (9 %) 4 (3 %) 21 (14 %)
Lung diseases 24 (8 %) 13 (9 %) 11 (7 %)
Sepsis 23 (8 %) 7 (5 %) 16 (11 %)
Hepatic encephalopathy 20 (7 %) 5 (4 %) 15 (10 %)
Pneumonia 16 (6 %) 5 (4 %) 11 (7 %)
Portal vein thrombosis 15 (5 %) 7 (5 %) 8 (5 %)
Pancreatitis 14 (5 %) 2 (1 %) 12 (8 %)
Peritonitis 14 (5 %) 2 (1 %) 12 (8 %)
Hemic disease 12 (4 %) 3 (2 %) 9 (6 %)
Others (benign tumors, urologic diseases, etc.) 10 (4 %) 4 (3 %) 6 (4 %)
Cytology result    
Positive 35 (12 %) 35 (26 %) 0 (0 %)
Negative 226 (80 %) 80 (60 %) 146 (98 %)
Suspicious 22 (8 %) 19 (14 %) 3 (2 %)
  1. Clinical data of 283 patients (134 cancer patients, 149 non-cancer patients) included in the study